ASCENT-05 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Gilead Sciences, Inc.
Start Date
May 14, 2024
End Date
April 30, 2029
Administered By
Duke Cancer Institute
Awarded By
Gilead Sciences, Inc.
Start Date
May 14, 2024
End Date
April 30, 2029